CMEonHIV.com is dedicated to providing online CME presentations (slides with voiceover) on HIV/AIDS for healthcare professionals given by local and international experts to keep you up-to-date on the ongoing developments in the field.
Conference
"NEV/EFA/ABA Trial - SWITCHING PROTEASE INHIBITORS TO NEVIRAPINE, EFAVIRENZ OR ABACAVIR: A RANDOMIZED, MULTICENTER, OPEN-LABEL, SIMPLIFICATION TRIAL" Dr. Jose Gatell (biography) English - 2002-04-13 - 27 minutes
(25 slides)
Summary : Background: In suppressed patients on 2 NRTI + 1 PI, switching from the PI to NEV, EFA or ABA is a common practice in order to improve convenience and compliance and potentially to prevent/revert side effects. Randomized studies comparing NEV, EFA and ABA have not been reported
Objective: To compare the virological response when switching from protease inhibitors (PI) to either nevirapine, efavirenz or abacavir in HIV-infected adults having suppresed viral load (VL<200 copies/mL) while on two NRTIs and at least one PI. Ref: NEFA Trial
USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.
